ClinicalTrials.gg
CompletedNCT03769116Updated Nov 14, 2024Results posted

A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)

A Phase 1/2 interventional study of delandistrogene moxeparvovec and placebo in Muscular Dystrophy, Duchenne, sponsored by Sarepta Therapeutics, Inc.. Completed at 2 sites in United States. Open to male participants aged 4 Years to 7 Years. Per ClinicalTrials.gov, last updated 2024-11-14.

Sponsored by Sarepta Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
4 Years to 7 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..

Enrollment
10th of 25
41 · median 24
Started
2018
with 4 others
Phase 1/2
5 of 27
none open now
Registered
15th of 27
by date

Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 10th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2018, is one of 5 in phase 1/2, and was the 15th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 7 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of exogenous gene transfer in DMD participants by measuring biological and clinical endpoints in three parts: two 48-week randomized, double-blinded, placebo-controlled periods (Part 1 and Part 2), and an open-label follow-up period (Part 3). Participants who are randomized to placebo in Part 1 will have the opportunity for treatment with delandistrogene moxeparvovec in Part 2.

In order to provide a uniform approach to monitoring long-term safety and efficacy in participants who received SRP-9001 in a clinical trial, the Sponsor has amended Study Completion for this study to occur at Week 130. Therefore, participants have transitioned and will complete the remainder of the Part 3 follow up visits in a long-term extension study, SRP-9001-305 (NCT05967351).

03

Conditions studied

  • Muscular Dystrophy, Duchenne

Keywords

  • Duchenne Muscular Dystrophy
  • Gene-Delivery
  • DMD
  • Ambulatory
  • Pediatric
  • North Star Ambulatory Assessment (NSAA)
  • Percent Dystrophin Positive Fibers (PDPF)
04

Who can participate

Ages eligible
4 Years to 7 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Established clinical diagnosis of DMD and documented dystrophin gene mutation of DMD phenotype.
  • Indication of symptomatic muscular dystrophy by protocol-specified criteria.
  • Ability to cooperate with motor assessment testing.
  • Stable dose equivalent of oral for at least 12 weeks.
  • A frameshift mutation contained between exons 18 and 58 (inclusive).

Exclusion criteria

Exclusion Criteria:

  • Impaired cardiovascular function on echocardiogram.
  • Prior or ongoing medical condition on physical examination, , or laboratory findings that could adversely affect participant safety, compromise completion of follow-up, or impair assessment of study results.
  • Exposure to another drug or exon skipping medication within 6 months of screening.
  • Exposure to an investigational or commercial gene therapy product.
  • Abnormal liver or renal function by protocol-specified criteria.

Other inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Delandistrogene Moxeparvovec in Part 1 Followed by Placebo in Part 2

    Participant will receive delandistrogene moxeparvovec at Part 1 followed by matching placebo at Part 2 followed by an open-label extension at Part 3.

    Genetic: delandistrogene moxeparvovec · Genetic: placebo

  • Experimental
    Placebo in Part 1 Followed by Delandistrogene Moxeparvovec in Part 2

    Participant will receive matching placebo at Part 1 followed by delandistrogene moxeparvovec at Part 2 followed by an open-label extension at Part 3.

    Genetic: delandistrogene moxeparvovec · Genetic: placebo

Interventions

  • Geneticdelandistrogene moxeparvovec

    Single IV infusion of delandistrogene moxeparvovec

    Also known as: SRP-9001, delandistrogene moxeparvovec-rokl, ELEVIDYS

  • Geneticplacebo

    Single IV infusion of matching placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline at Week 12 in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression as Measured by Western Blot Adjusted by Muscle Content

    Baseline muscle biopsies with ultrasound guidance were performed pre-treatment and post-treatment (Week 12) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined by Western Blot. Dystrophin protein was measured and then adjusted based on the percentage of muscle content in the biopsy sample. An increase in protein expression indicates production of the delandistrogene moxeparvovec dystrophin protein.

    Time frame: Baseline, Week 12 (Part 1)

  2. Change From Baseline at Week 48 in NSAA Total Score

    The NSAA is a healthcare provider administered scale that rates performance of various motor abilities in ambulant children with Duchenne Muscular Dystrophy and is used to monitor disease progression and treatment effects. During assessment, participants are asked to perform 17 different functional activities that are graded as: 2 - "Normal" - no obvious modification of activity; 1 - Modified method but achieves goal independent of assistance; 0 - Unable to achieve independently. The NSAA total score is defined as the sum of all 17 items, ranging from 0 (worst) to 34 (best). The response vector consists of the change from baseline in NSAA total score at the post-baseline visit. The model includes the covariates of treatment group, visit, treatment group by visit interaction, age group, baseline NSAA total score, and baseline NSAA total score by visit interaction. All covariates are fixed effects in this analysis. An increase in score indicates an improvement in motor function.

    Time frame: Baseline, Week 48 (Part 1)

Secondary outcomes

  1. Change From Baseline at Week 48 in Time to Rise From the Floor

    This functional assessment was performed as a part of the NSAA and measures the time taken to rise from supine to standing. All functional assessments were administered by a clinical evaluator. A decrease in time indicates an improvement in motor function.

    Time frame: Baseline, Week 48 (Part 1)

  2. Change From Baseline at Week 48 in Time to Ascend 4 Steps

    This functional assessment measures the time taken to climb 4 steps. All functional assessments were administered by a clinical evaluator. A decrease in time indicates an improvement in motor function.

    Time frame: Baseline, Week 48 (Part 1)

  3. Change From Baseline at Week 48 in Time of 10-meter Timed Test

    This functional assessment measures the time needed to move 10 meters. All functional assessments were administered by a clinical evaluator. A decrease in time indicates an improvement in motor function.

    Time frame: Baseline, Week 48 (Part 1)

  4. Change From Baseline at Week 48 in Time of 100-meter Timed Test

    This functional assessment measures the time needed to move 100 meters. All functional assessments were administered by a clinical evaluator. A decrease in time indicates an improvement in motor function.

    Time frame: Baseline, Week 48 (Part 1)

  5. Change From Baseline at Week 12 in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression Measured by Immunofluorescence (IF) Fiber Intensity

    Baseline muscle biopsies were performed pre-treatment and post-treatment (Week 12) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined using IF fiber intensity. Automated software was used to quantify the intensity of dystrophin expression post-treatment compared to pre-treatment and reviewed by trained evaluators. An increase in IF fiber intensity (percent control) indicates increased delandistrogene moxeparvovec dystrophin expression, relative to non-dystrophic muscle (the control).

    Time frame: Baseline, Week 12 (Part 1)

  6. Change From Baseline at Week 12 in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression Measured by IF Percent Dystrophin Positive Fibers (PDPF)

    Baseline muscle biopsies were performed pre-treatment and post-treatment (Week 12) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined by IF PDPF. Automated software was used to quantify the intensity of dystrophin expression post-treatment compared to pre-treatment. The number of muscle fibers expressing dystrophin was quantified by independent trained evaluators. An increase in IF PDPF indicates the number of muscle fibers with increased delandistrogene moxeparvovec dystrophin expression.

    Time frame: Baseline, Week 12 (Part 1)

  7. Participants Experiencing Adverse Events (AEs) Since Treatment With Delandistrogene Moxeparvovec

    Participants experiencing AEs are reported based upon the time to AE onset after delandistrogene moxeparvovec infusion. Each analysis set includes data from both arms and is based upon the Delandistrogene Moxeparvovec-treated Population: all participants who were treated with delandistrogene moxeparvovec in Part 1 or Part 2. 'Delandistrogene Moxeparvovec switched over to Placebo' participants received delandistrogene moxeparvovec in Part 1, followed by placebo in Part 2. AEs experienced by participants during Parts 1, 2, and 3 of the study are reported. 'Placebo switched over to Delandistrogene Moxeparvovec' participants received placebo in Part 1, followed by delandistrogene moxeparvovec in Part 2. AEs experienced by participants during Parts 2 and 3 of the study are reported. No intervention was administered during Part 3. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.

    Time frame: Day 1 through final study visit (approximately 4.6 years)

Other outcomes

  1. Baseline NSAA Total Score by Age Group

    The NSAA is a healthcare provider administered scale that rates performance of various motor abilities in ambulant children with Duchenne Muscular Dystrophy and is used to monitor disease progression and treatment effects. During assessment, participants are asked to perform 17 different functional activities that are graded as: 2 - "Normal" - no obvious modification of activity; 1 - Modified method but achieves goal independent of assistance; 0 - Unable to achieve independently. The NSAA total score is defined as the sum of all 17 items, ranging from 0 (worst) to 34 (best). This outcome measure presents only the baseline NSAA total score of the ITT population by the following age groups: 4-5 years old; 6-7 years old.

    Time frame: Baseline

  2. Change From Baseline at Week 48 in NSAA Total Score by Age Group

    The NSAA is a healthcare provider administered scale that rates performance of various motor abilities in ambulant children with Duchenne Muscular Dystrophy and is used to monitor disease progression and treatment effects. During assessment, participants are asked to perform 17 different functional activities that are graded as: 2 - "Normal" - no obvious modification of activity; 1 - Modified method but achieves goal independent of assistance; 0 - Unable to achieve independently. The NSAA total score is defined as the sum of all 17 items, ranging from 0 (worst) to 34 (best). The response vector consists of the change from baseline in NSAA total score at the post-baseline visit. The model includes the covariates of treatment group, visit, treatment group by visit interaction, age group, baseline NSAA total score, and baseline NSAA total score by visit interaction. All covariates are fixed effects in this analysis. An increase in score indicates an improvement in motor function.

    Time frame: Baseline, Week 48 (Part 1)

07

Results

Posted Sep 15, 2023
Limitations and caveats
Caution should be taken in interpreting the treatment effect on the 6-7 years-old age group due to differences in baseline prognostic functional characteristics for certain assessments in treated versus placebo in Part 1.

Participant flow

This was a 3-part clinical study of a single dose of delandistrogene moxeparvovec. Participants were randomized to receive delandistrogene moxeparvovec in one of two 48-week periods (Part 1 or Part 2) via a crossover study design. Part 3 was an open-label follow up.

Part 1 - Double Blind
Participant flow — Part 1 - Double Blind
MilestoneDelandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene Moxeparvovec
Started2021
Received at least 1 dose of study drug2021
Completed2021
Not completed00
Part 2 - Double Blind
Participant flow — Part 2 - Double Blind
MilestoneDelandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene Moxeparvovec
Started2021
Received at least 1 dose of study drug2021
Completed2021
Not completed00
Part 3 - Open Label
Participant flow — Part 3 - Open Label
MilestoneDelandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene Moxeparvovec
Started2021
Received at least 1 dose of study drug00
Completed1719
Not completed32
Withdrew: Study terminated by sponsor12
Withdrew: Physician decision10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryChange From Baseline at Week 12 in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression as Measured by Western Blot Adjusted by Muscle Content

Baseline muscle biopsies with ultrasound guidance were performed pre-treatment and post-treatment (Week 12) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined by Western Blot. Dystrophin protein was measured and then adjusted based on the percentage of muscle content in the biopsy sample. An increase in protein expression indicates production of the delandistrogene moxeparvovec dystrophin protein.

Time frame:
Baseline, Week 12 (Part 1)
Reported as:
Mean · percent normal
Change From Baseline at Week 12 in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression as Measured by Western Blot Adjusted by Muscle Content
percent normalDelandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene Moxeparvovec
Baseline4.23 ± 6.831.91 ± 1.28
Change from Baseline23.82 ± 39.760.14 ± 1.24
Statistical analysis
  • Delandistrogene Moxeparvovec Switched Over to Placebo vs Placebo Switched Over to Delandistrogene Moxeparvovec · Wilcoxon rank sum test · p = < 0.0001 · Hodges-lehmann treatment diff: 6.11 · 95% CI 2.08 to 12.58
PrimaryChange From Baseline at Week 48 in NSAA Total Score

The NSAA is a healthcare provider administered scale that rates performance of various motor abilities in ambulant children with Duchenne Muscular Dystrophy and is used to monitor disease progression and treatment effects. During assessment, participants are asked to perform 17 different functional activities that are graded as: 2 - "Normal" - no obvious modification of activity; 1 - Modified method but achieves goal independent of assistance; 0 - Unable to achieve independently. The NSAA total score is defined as the sum of all 17 items, ranging from 0 (worst) to 34 (best). The response vector consists of the change from baseline in NSAA total score at the post-baseline visit. The model includes the covariates of treatment group, visit, treatment group by visit interaction, age group, baseline NSAA total score, and baseline NSAA total score by visit interaction. All covariates are fixed effects in this analysis. An increase in score indicates an improvement in motor function.

Time frame:
Baseline, Week 48 (Part 1)
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 48 in NSAA Total Score
score on a scaleDelandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene Moxeparvovec
Change From Baseline at Week 48 in NSAA Total Score1.7 ± 0.60.9 ± 0.6
Statistical analysis
  • Delandistrogene Moxeparvovec Switched Over to Placebo vs Placebo Switched Over to Delandistrogene Moxeparvovec · Mixed-model for Repeated Measures · p = = 0.3730 · Lsm change difference: 0.8 · 95% CI -1.0 to 2.7
SecondaryChange From Baseline at Week 48 in Time to Rise From the Floor

This functional assessment was performed as a part of the NSAA and measures the time taken to rise from supine to standing. All functional assessments were administered by a clinical evaluator. A decrease in time indicates an improvement in motor function.

Time frame:
Baseline, Week 48 (Part 1)
Reported as:
Least squares mean · second
Change From Baseline at Week 48 in Time to Rise From the Floor
secondDelandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene Moxeparvovec
Change From Baseline at Week 48 in Time to Rise From the Floor-0.15 ± 0.250.35 ± 0.23
SecondaryChange From Baseline at Week 48 in Time to Ascend 4 Steps

This functional assessment measures the time taken to climb 4 steps. All functional assessments were administered by a clinical evaluator. A decrease in time indicates an improvement in motor function.

Time frame:
Baseline, Week 48 (Part 1)
Reported as:
Least squares mean · second
Change From Baseline at Week 48 in Time to Ascend 4 Steps
secondDelandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene Moxeparvovec
Change From Baseline at Week 48 in Time to Ascend 4 Steps0.17 ± 0.260.03 ± 0.26
SecondaryChange From Baseline at Week 48 in Time of 10-meter Timed Test

This functional assessment measures the time needed to move 10 meters. All functional assessments were administered by a clinical evaluator. A decrease in time indicates an improvement in motor function.

Time frame:
Baseline, Week 48 (Part 1)
Reported as:
Least squares mean · second
Change From Baseline at Week 48 in Time of 10-meter Timed Test
secondDelandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene Moxeparvovec
Change From Baseline at Week 48 in Time of 10-meter Timed Test0.59 ± 0.200.10 ± 0.19
SecondaryChange From Baseline at Week 48 in Time of 100-meter Timed Test

This functional assessment measures the time needed to move 100 meters. All functional assessments were administered by a clinical evaluator. A decrease in time indicates an improvement in motor function.

Time frame:
Baseline, Week 48 (Part 1)
Reported as:
Least squares mean · second
Change From Baseline at Week 48 in Time of 100-meter Timed Test
secondDelandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene Moxeparvovec
Change From Baseline at Week 48 in Time of 100-meter Timed Test4.29 ± 3.926.28 ± 3.83
SecondaryChange From Baseline at Week 12 in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression Measured by Immunofluorescence (IF) Fiber Intensity

Baseline muscle biopsies were performed pre-treatment and post-treatment (Week 12) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined using IF fiber intensity. Automated software was used to quantify the intensity of dystrophin expression post-treatment compared to pre-treatment and reviewed by trained evaluators. An increase in IF fiber intensity (percent control) indicates increased delandistrogene moxeparvovec dystrophin expression, relative to non-dystrophic muscle (the control).

Time frame:
Baseline, Week 12 (Part 1)
Reported as:
Mean · fiber intensity percent control
Change From Baseline at Week 12 in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression Measured by Immunofluorescence (IF) Fiber Intensity
fiber intensity percent controlDelandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene Moxeparvovec
Change From Baseline at Week 12 in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression Measured by Immunofluorescence (IF) Fiber Intensity0.06 ± 0.110.00 ± 0.02
SecondaryChange From Baseline at Week 12 in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression Measured by IF Percent Dystrophin Positive Fibers (PDPF)

Baseline muscle biopsies were performed pre-treatment and post-treatment (Week 12) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined by IF PDPF. Automated software was used to quantify the intensity of dystrophin expression post-treatment compared to pre-treatment. The number of muscle fibers expressing dystrophin was quantified by independent trained evaluators. An increase in IF PDPF indicates the number of muscle fibers with increased delandistrogene moxeparvovec dystrophin expression.

Time frame:
Baseline, Week 12 (Part 1)
Reported as:
Mean · percent dystrophin positive fibers
Change From Baseline at Week 12 in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression Measured by IF Percent Dystrophin Positive Fibers (PDPF)
percent dystrophin positive fibersDelandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene Moxeparvovec
Change From Baseline at Week 12 in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression Measured by IF Percent Dystrophin Positive Fibers (PDPF)23.88 ± 25.585.09 ± 12.96
Other pre-specifiedBaseline NSAA Total Score by Age Group

The NSAA is a healthcare provider administered scale that rates performance of various motor abilities in ambulant children with Duchenne Muscular Dystrophy and is used to monitor disease progression and treatment effects. During assessment, participants are asked to perform 17 different functional activities that are graded as: 2 - "Normal" - no obvious modification of activity; 1 - Modified method but achieves goal independent of assistance; 0 - Unable to achieve independently. The NSAA total score is defined as the sum of all 17 items, ranging from 0 (worst) to 34 (best). This outcome measure presents only the baseline NSAA total score of the ITT population by the following age groups: 4-5 years old; 6-7 years old.

Time frame:
Baseline
Reported as:
Mean · score on a scale
Baseline NSAA Total Score by Age Group
score on a scaleDelandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene Moxeparvovec
Age Group: 4-5 years old20.1 ± 1.920.4 ± 2.7
Age Group: 6-7 years old19.6 ± 4.124.0 ± 2.9
Other pre-specifiedChange From Baseline at Week 48 in NSAA Total Score by Age Group

The NSAA is a healthcare provider administered scale that rates performance of various motor abilities in ambulant children with Duchenne Muscular Dystrophy and is used to monitor disease progression and treatment effects. During assessment, participants are asked to perform 17 different functional activities that are graded as: 2 - "Normal" - no obvious modification of activity; 1 - Modified method but achieves goal independent of assistance; 0 - Unable to achieve independently. The NSAA total score is defined as the sum of all 17 items, ranging from 0 (worst) to 34 (best). The response vector consists of the change from baseline in NSAA total score at the post-baseline visit. The model includes the covariates of treatment group, visit, treatment group by visit interaction, age group, baseline NSAA total score, and baseline NSAA total score by visit interaction. All covariates are fixed effects in this analysis. An increase in score indicates an improvement in motor function.

Time frame:
Baseline, Week 48 (Part 1)
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 48 in NSAA Total Score by Age Group
score on a scaleDelandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene Moxeparvovec
Age Group: 4-5 years old4.3 ± 0.61.9 ± 0.6
Age Group: 6-7 years old-0.2 ± 0.70.5 ± 0.7
Statistical analysis
  • Delandistrogene Moxeparvovec Switched Over to Placebo vs Placebo Switched Over to Delandistrogene Moxeparvovec · Mixed-model for Repeated Measures · p = = 0.0172 · Lsm change difference: 2.5 · 95% CI 0.5 to 4.4
  • Delandistrogene Moxeparvovec Switched Over to Placebo vs Placebo Switched Over to Delandistrogene Moxeparvovec · Mixed-model for Repeated Measures · p = = 0.5384 · Lsm change difference: -0.7 · 95% CI -3.0 to 1.6
SecondaryParticipants Experiencing Adverse Events (AEs) Since Treatment With Delandistrogene Moxeparvovec

Participants experiencing AEs are reported based upon the time to AE onset after delandistrogene moxeparvovec infusion. Each analysis set includes data from both arms and is based upon the Delandistrogene Moxeparvovec-treated Population: all participants who were treated with delandistrogene moxeparvovec in Part 1 or Part 2. 'Delandistrogene Moxeparvovec switched over to Placebo' participants received delandistrogene moxeparvovec in Part 1, followed by placebo in Part 2. AEs experienced by participants during Parts 1, 2, and 3 of the study are reported. 'Placebo switched over to Delandistrogene Moxeparvovec' participants received placebo in Part 1, followed by delandistrogene moxeparvovec in Part 2. AEs experienced by participants during Parts 2 and 3 of the study are reported. No intervention was administered during Part 3. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.

Time frame:
Day 1 through final study visit (approximately 4.6 years)
Reported as:
Count of participants · Participants
Participants Experiencing Adverse Events (AEs) Since Treatment With Delandistrogene Moxeparvovec
ParticipantsLess Than 1 Year After Delandistrogene Moxeparvovec Infusion1 to 2 Years After Delandistrogene Moxeparvovec Infusion2 to 3 Years After Delandistrogene Moxeparvovec Infusion3 to 4 Years After Delandistrogene Moxeparvovec InfusionMore Than 4 Years After Delandistrogene Moxeparvovec Infusion
Treatment-emergent AE (TEAE)413733173
Serious AE (SAE)51200
Treatment-related TEAE372100
Treatment-related SAE30000
Any AE leading to study discontinuation00000
Death00000

Adverse events

Collected over Day 1 through final study visit (approximately 4.6 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Delandistrogene Moxeparvovec0/20 (0%)3/20 (15%)20/20 (100%)
Part 1: Placebo0/21 (0%)2/21 (9.5%)21/21 (100%)
Part 2: Delandistrogene Moxeparvovec Switched Over to Placebo0/20 (0%)2/20 (10%)20/20 (100%)
Part 2: Placebo Switched Over to Delandistrogene Moxeparvovec0/21 (0%)1/21 (4.8%)21/21 (100%)
Part 3: Delandistrogene Moxeparvovec Switched Over to Placebo0/20 (0%)0/20 (0%)18/20 (90%)
Part 3: Placebo Switched Over to Delandistrogene Moxeparvovec0/21 (0%)2/21 (9.5%)19/21 (90.5%)
Most frequent serious events
Most frequent serious events
EventPart 1: Delandistrogene MoxeparvovecPart 1: PlaceboPart 2: Delandistrogene Moxeparvovec Switched Over to PlaceboPart 2: Placebo Switched Over to Delandistrogene MoxeparvovecPart 3: Delandistrogene Moxeparvovec Switched Over to PlaceboPart 3: Placebo Switched Over to Delandistrogene Moxeparvovec
RhabdomyolysisMusculoskeletal and connective tissue disorders2/201/210/200/210/201/21
Femur fractureInjury, poisoning and procedural complications0/200/212/200/210/201/21
Liver injuryHepatobiliary disorders1/200/210/200/210/200/21
HypertransaminasaemiaHepatobiliary disorders1/200/210/200/210/200/21
Humerus fractureInjury, poisoning and procedural complications0/201/210/200/210/200/21
AppendicitisInfections and infestations0/200/210/201/210/200/21
Most frequent other events
Showing 10 of 72
Most frequent other events
EventPart 1: Delandistrogene MoxeparvovecPart 1: PlaceboPart 2: Delandistrogene Moxeparvovec Switched Over to PlaceboPart 2: Placebo Switched Over to Delandistrogene MoxeparvovecPart 3: Delandistrogene Moxeparvovec Switched Over to PlaceboPart 3: Placebo Switched Over to Delandistrogene Moxeparvovec
VomitingGastrointestinal disorders13/207/210/2016/211/203/21
Decreased appetiteMetabolism and nutrition disorders8/200/211/2015/210/200/21
Upper respiratory tract infectionInfections and infestations13/2013/218/207/219/209/21
NauseaGastrointestinal disorders7/202/212/2011/210/200/21
CoughRespiratory, thoracic and mediastinal disorders9/206/213/201/212/204/21
COVID-19Infections and infestations0/200/210/202/219/209/21
Viral infectionInfections and infestations8/209/213/200/212/203/21
Procedural painInjury, poisoning and procedural complications5/207/216/209/210/202/21
IrritabilityPsychiatric disorders3/201/215/209/211/202/21
Abdominal pain upperGastrointestinal disorders6/204/212/208/210/200/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)Delandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene MoxeparvovecTotal
Mean6.29 ± 1.196.24 ± 1.136.27 ± 1.15
Age, Customized
Age, Customized(Participants)Delandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene MoxeparvovecTotal
In utero000
Preterm newborn infants (gestational age < 37 wks)000
Newborns (0-27 days)000
Infants and toddlers (28 days-23 months)000
Children (2-11 years)202141
Adolescents (12-17 years)000
Adults (18-64 years)000
From 65-84 years000
85 years and over000
Sex: Female, Male
Sex: Female, Male(Participants)Delandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene MoxeparvovecTotal
Female000
Male202141
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Delandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene MoxeparvovecTotal
Hispanic or Latino145
Not Hispanic or Latino191635
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Delandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene MoxeparvovecTotal
American Indian or Alaska Native000
Asian415
Native Hawaiian or Other Pacific Islander000
Black or African American000
White131730
More than one race000
Unknown or Not Reported336
North Star Ambulatory Assessment (NSAA) Group
North Star Ambulatory Assessment (NSAA) Group(Participants)Delandistrogene Moxeparvovec Switched Over to PlaceboPlacebo Switched Over to Delandistrogene MoxeparvovecTotal
NSAA baseline total score ≥ median score81523
NSAA baseline total score < median score12618
08

Study locations

2 sites
  • David Geffen School of Medicine at UCLA
    Los Angeles, California 90095, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Dec 2020, 24 months.

Results were first posted in Sep 2023, 2 years 9 months after primary completion. A results delay was requested in Dec 2021.

Of 23 phase 1/2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2018
First posted
Dec 7, 2018
StartActual
Dec 5, 2018
Primary completionActual
Dec 8, 2020
CompletionActual
Aug 16, 2023
Results delay requested
Dec 1, 2021
Results first posted
Sep 15, 2023
Last update
Nov 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03769116
Responsible party
Sponsor
First posted
Dec 7, 2018
Start date
Dec 5, 2018
Primary completion
Dec 8, 2020
Completion
Aug 16, 2023
Results posted
Sep 15, 2023
Last update
Nov 14, 2024

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion